These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37431844)

  • 61. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study.
    Cariou B; Goronflot T; Rimbert A; Boullu S; Le May C; Moulin P; Pichelin M; Potier L; Smati S; Sultan A; Tramunt B; Wargny M; Gourdy P; Hadjadj S;
    Diabetes Metab; 2021 Mar; 47(2):101202. PubMed ID: 33091555
    [TBL] [Abstract][Full Text] [Related]  

  • 63. NEUROPROTECTIVE AND ANTIOXIDANT POTENTIAL OF MONTELUKAST-ACETYLCYSTEINE COMBINATION THERAPY FOR BRAIN PROTECTION IN PATIENTS WITH COVID-19 INDUCED PNEUMONIA.
    Samsonia M; Kandelaki M; Baratashvili N; Gvaramia L
    Georgian Med News; 2023 Feb; (335):111-118. PubMed ID: 37042600
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Diabetic Ketoacidosis and COVID-19: A Retrospective Observational Study.
    Nagdev G; Chavan G; Gadkari C; Sahu G
    Cureus; 2022 Oct; 14(10):e30895. PubMed ID: 36465737
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Laboratory Characteristics on SARS-CoV-2 Infection among Patients with Diabetes Mellitus: A Single-Center Retrospective Study.
    Salem RO; Nuzhat A; Zaheer S; Kallash MA
    J Diabetes Res; 2023; 2023():9940250. PubMed ID: 36712996
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Admission eGFR predicts in-hospital mortality independently of admission glycemia and C-peptide in patients with type 2 diabetes mellitus and COVID-19.
    Infante M; Pieri M; Lupisella S; Mohamad A; Bernardini S; Della-Morte D; Fabbri A; De Stefano A; Iannetta M; Ansaldo L; Crea A; Andreoni M; Morello M
    Curr Med Res Opin; 2023 Apr; 39(4):505-516. PubMed ID: 36749566
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Risk Factors Potentially Influencing Hospital Admission in People with Diabetes, Following SARS-CoV-2 Infection: A Population-Level Analysis.
    Heald AH; Jenkins DA; Williams R; Sperrin M; Fachim H; Mudaliar RN; Syed A; Naseem A; Gibson JM; Bowden Davies KA; Peek N; Anderson SG; Peng Y; Ollier W
    Diabetes Ther; 2022 May; 13(5):1007-1021. PubMed ID: 35325361
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
    Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
    Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort.
    Kim HJ; Lee S; Chun KH; Jeon JY; Han SJ; Kim DJ; Kim YS; Woo JT; Nam MS; Baik SH; Ahn KJ; Lee KW
    Medicine (Baltimore); 2018 Feb; 97(8):e0036. PubMed ID: 29465545
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?].
    Pan Y; Han R; He Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Sep; 32(9):1131-1134. PubMed ID: 33081905
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of data mining approaches to explore the association between type 2 diabetes mellitus with SARS-CoV-2.
    Ghazizadeh H; Shakour N; Ghoflchi S; Mansoori A; Saberi-Karimiam M; Rashidmayvan M; Ferns G; Esmaily H; Ghayour-Mobarhan M
    BMC Pulm Med; 2023 Jun; 23(1):203. PubMed ID: 37308948
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
    Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
    Front Immunol; 2021; 12():752233. PubMed ID: 34899701
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of Metformin Treatment with Reduced Severity of Diabetic Retinopathy in Type 2 Diabetic Patients.
    Li Y; Ryu C; Munie M; Noorulla S; Rana S; Edwards P; Gao H; Qiao X
    J Diabetes Res; 2018; 2018():2801450. PubMed ID: 29854819
    [TBL] [Abstract][Full Text] [Related]  

  • 74. COVID-19 and diabetes mellitus: a review of the incidence, pathophysiology and management of diabetes during the pandemic.
    Faruqi J; Balasubramanyam A
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):167-179. PubMed ID: 36797835
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus.
    Yen FS; Wang SI; Lin SY; Wei JC
    Diabetes Res Clin Pract; 2023 Jun; 200():110692. PubMed ID: 37156428
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer.
    Linkeviciute-Ulinskiene D; Patasius A; Kincius M; Zabuliene L; Smailyte G
    Scand J Urol; 2020 Oct; 54(5):401-407. PubMed ID: 32748714
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients.
    Hasan SS; Kow CS; Bain A; Kavanagh S; Merchant HA; Hadi MA
    Expert Opin Pharmacother; 2021 Feb; 22(2):229-240. PubMed ID: 33054481
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Diabetic Covid-19 severity: Impaired glucose tolerance and pathologic bone loss.
    Behera J; Ison J; Voor MJ; Tyagi SC; Tyagi N
    Biochem Biophys Res Commun; 2022 Sep; 620():180-187. PubMed ID: 35803174
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.